Literature DB >> 24835496

The future potential for cocaine vaccines.

Frank M Orson1, Rongfu Wang, Stephen Brimijoin, Berma M Kinsey, Rana Ak Singh, Muthu Ramakrishnan, Helen Y Wang, Thomas R Kosten.   

Abstract

INTRODUCTION: Addiction to cocaine is a major problem around the world, but especially in developed countries where the combination of wealth and user demand has created terrible social problems. Although only some users become truly addicted, those who are often succumb to a downward spiral in their lives from which it is very difficult to escape. From the medical perspective, the lack of effective and safe, non-addictive therapeutics has instigated efforts to develop alternative approaches for treatment, including anticocaine vaccines designed to block cocaine's pharmacodynamic effects. AREAS COVERED: This paper discusses the implications of cocaine pharmacokinetics for robust vaccine antibody responses, the results of human vaccine clinical trials, new developments in animal models for vaccine evaluation, alternative vaccine formulations and complementary therapy to enhance anticocaine effectiveness. EXPERT OPINION: Robust anti-cocaine antibody responses are required for benefit to cocaine abusers, but since any reasonably achievable antibody level can be overcome with higher drug doses, sufficient motivation to discontinue use is also essential so that the relative barrier to cocaine effects will be appropriate for each individual. Combining a vaccine with achievable levels of an enzyme to hydrolyze cocaine to inactive metabolites, however, may substantially increase the blockade and improve treatment outcomes.

Entities:  

Keywords:  addiction; adjuvant; antibody; butyrylcholinesterase; cocaine; gene therapy; hydrolase; vaccine

Mesh:

Substances:

Year:  2014        PMID: 24835496      PMCID: PMC4154474          DOI: 10.1517/14712598.2014.920319

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  114 in total

Review 1.  Immunogenomics and systems biology of vaccines.

Authors:  Luigi Buonaguro; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Risk of becoming cocaine dependent: epidemiological estimates for the United States, 2000-2001.

Authors:  Megan S O'Brien; James C Anthony
Journal:  Neuropsychopharmacology       Date:  2005-05       Impact factor: 7.853

3.  NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways.

Authors:  Jun Cui; Liang Zhu; Xiaojun Xia; Helen Y Wang; Xavier Legras; Jun Hong; Jiabing Ji; Pingping Shen; Shu Zheng; Zhijian J Chen; Rong-Fu Wang
Journal:  Cell       Date:  2010-04-30       Impact factor: 41.582

4.  The global epidemiology and burden of psychostimulant dependence: findings from the Global Burden of Disease Study 2010.

Authors:  Louisa Degenhardt; Amanda J Baxter; Yong Yi Lee; Wayne Hall; Grant E Sara; Nicole Johns; Abraham Flaxman; Harvey A Whiteford; Theo Vos
Journal:  Drug Alcohol Depend       Date:  2014-01-27       Impact factor: 4.492

5.  Generation of hematopoietic humanized mice in the newborn BALB/c-Rag2null Il2rγnull mouse model: a multivariable optimization approach.

Authors:  Julie Lang; Nicholas Weiss; Brian M Freed; Raul M Torres; Roberta Pelanda
Journal:  Clin Immunol       Date:  2011-04-14       Impact factor: 3.969

6.  Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy.

Authors:  Sergey S Seregin; Daniel M Appledorn; Aaron J McBride; Nathaniel J Schuldt; Yasser A Aldhamen; Tyler Voss; Junping Wei; Matthew Bujold; William Nance; Sarah Godbehere; Andrea Amalfitano
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

Review 7.  Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse.

Authors:  Stephen Brimijoin; Xiaoyun Shen; Frank Orson; Thomas Kosten
Journal:  Expert Rev Vaccines       Date:  2013-03       Impact factor: 5.217

8.  Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway.

Authors:  Guangyong Peng; Helen Y Wang; Weiyi Peng; Yukiko Kiniwa; Kook Heon Seo; Rong-Fu Wang
Journal:  Immunity       Date:  2007-07-26       Impact factor: 31.745

9.  Associations between cytokine/cytokine receptor single nucleotide polymorphisms and humoral immunity to measles, mumps and rubella in a Somali population.

Authors:  N Dhiman; I G Ovsyannikova; R A Vierkant; V S Pankratz; R M Jacobson; G A Poland
Journal:  Tissue Antigens       Date:  2008-09

Review 10.  Advances in high-capacity extrachromosomal vector technology: episomal maintenance, vector delivery, and transgene expression.

Authors:  Michele M P Lufino; Pauline A H Edser; Richard Wade-Martins
Journal:  Mol Ther       Date:  2008-07-15       Impact factor: 11.454

View more
  9 in total

1.  Suppression of Cocaine-Evoked Hyperactivity by Self-Adjuvanting and Multivalent Peptide Nanofiber Vaccines.

Authors:  Jai S Rudra; Ye Ding; Harshini Neelakantan; Chunyong Ding; Rajagopal Appavu; Sonja Stutz; Joshua D Snook; Haiying Chen; Kathryn A Cunningham; Jia Zhou
Journal:  ACS Chem Neurosci       Date:  2016-03-08       Impact factor: 4.418

2.  Enhancing Efficacy and Stability of an Antiheroin Vaccine: Examination of Antinociception, Opioid Binding Profile, and Lethality.

Authors:  Candy S Hwang; Paul T Bremer; Cody J Wenthur; Sam On Ho; SuMing Chiang; Beverly Ellis; Bin Zhou; Gary Fujii; Kim D Janda
Journal:  Mol Pharm       Date:  2018-02-19       Impact factor: 4.939

Review 3.  Biologics to treat substance use disorders: Current status and new directions.

Authors:  Marco Pravetoni
Journal:  Hum Vaccin Immunother       Date:  2016-07-21       Impact factor: 3.452

Review 4.  Psychopharmacology: neuroimmune signaling in psychiatric disease-developing vaccines against abused drugs using toll-like receptor agonists.

Authors:  Fang Yang; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2019-02-06       Impact factor: 4.530

Review 5.  Medications for substance use disorders (SUD): emerging approaches.

Authors:  Eduardo R Butelman; Mary Jeanne Kreek
Journal:  Expert Opin Emerg Drugs       Date:  2017-10-30       Impact factor: 4.191

6.  The GNE-KLH anti-cocaine vaccine protects dams and offspring from cocaine-induced effects during the prenatal and lactating periods.

Authors:  Paulo Sérgio de Almeida Augusto; Raissa Lima Gonçalves Pereira; Sordaini Maria Caligiorne; Brian Sabato; Bruna Rodrigues Dias Assis; Larissa Pires do Espírito Santo; Karine Dias Dos Reis; Gisele Assis Castro Goulart; Ângelo de Fátima; Maila de Castro Lourenço das Neves; Frederico Duarte Garcia
Journal:  Mol Psychiatry       Date:  2021-08-11       Impact factor: 15.992

7.  Flagellin as carrier and adjuvant in cocaine vaccine development.

Authors:  Jonathan W Lockner; Lisa M Eubanks; Jennifer L Choi; Jenny M Lively; Joel E Schlosburg; Karen C Collins; Daniel Globisch; Robin J Rosenfeld-Gunn; Ian A Wilson; Kim D Janda
Journal:  Mol Pharm       Date:  2015-01-07       Impact factor: 4.939

8.  Are therapeutic vaccines an answer to the global problem of drug and alcohol abuse?

Authors:  Dick B S Brashier; Ashok Kumar Sharma; Neha Akhoon
Journal:  Indian J Pharmacol       Date:  2016 Sep-Oct       Impact factor: 1.200

9.  Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse.

Authors:  M D Raleigh; S J Peterson; M Laudenbach; F Baruffaldi; F I Carroll; S D Comer; H A Navarro; T L Langston; S P Runyon; S Winston; M Pravetoni; P R Pentel
Journal:  PLoS One       Date:  2017-12-01       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.